BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel 2023 CNS Days taking place March 28-29, 2023.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2022 and provided a business update.

Assembly Biosciences, Inc. (Nasdaq: ASMB) today provided an update on its investigational next-generation hepatitis B virus (HBV) core inhibitors, ABI-H3733 (3733) and ABI-4334 (4334), and reported financial results and recent highlights for the fourth quarter and year ended December 31, 2022.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and twelve months ended December 31, 2022 and provided a corporate update.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2022 ended December 31, 2022.

CONMED Corporation announced that its Annual Meeting of Stockholders will be held on Wednesday, May 24, 2023, at 1:30 p.m. ET at its corporate headquarters at 11311 Concept Boulevard, Largo FL and through the internet virtually.

Gracell Biotechnologies Inc. announced that the management team will participate in two upcoming investor conferences.

Genomadix, based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” (Cube CYP2C19 test), an automated sample-to-result PCR test.